Invent: Life Sciences

TTP Trailer - transcript

Stuart: The life sciences are about to transform human health in ways we can barely imagine.
We are in the midst of a revolution in the way we conduct pharmaceutical research and in how we manufacture advanced therapies. And it’s patients, suffering from some of humanity’s most intractable diseases who stand to benefit.
In this podcast, brought to you by technology and product development company TTP, we’ll investigate these develop-ments and the many profound ways they’ll shape medicine in the future.
Welcome back to Invent: Life Sciences.
Bas: We’ve been hugely, hugely successful.
Alexander: We can harness that knowledge, which is immensely important.
Diana: As a scientist, it is super exciting to look at this. There’s so much you can learn.
Stuart: Previously on the podcast, we highlighted the impact of biology and technology on the wider life sciences industry.
In Season 2, we now turn our focus onto advances driving forward the pharmaceutical sector, and how life scientists are dedicating their lives to bringing the benefits of medicine to those who need it most.
Bas: It’s not just a way to reduce the use of animals - nine times out of ten it’s actually a better solution.
Rabia: We could really make an impact to some of the most significant challenges.
Dan: I’m very optimistic. But I’m an optimistic guy.
Stuart: We’ll ask: how can overcoming the blood brain barrier defend us from Alzheimer's?
What sort of partnerships make the most impact in cell and gene therapy?
Could under-represented groups benefit from new drug discovery methods?
Alexander: You need to understand the problem from different perspectives, before you come up with a solution.
Sylvia: It’s a difficult question. [laughs]
Stuart: All over the world, scientists are pushing the boundaries far beyond what was once thought possible.
On this podcast, we’ll hear from those working on the cutting edge to invent, develop, and promote these new technologies.
Rabia: 20 years from now I think we’re going to have more RNA targeting companies than we have protein targeting companies.
Sylvia: With organoids, we’re bringing a new perspective of these kinds of diseases.
Marina: You could use image-guided machine learning to identify the locations of nuclei in cells.
Stuart: Join me, Stuart Lowe, as we plug into Invent: Life Sciences.
We’ll be with you throughout the autumn taking you on a journey of discovery about our collective health.
Ready to go? Let’s plug in.